OakChart

Zura Bio Ltd

ZURAHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 9:53 AM ET

1.40-0.01 (-0.36%)
2026-11-11 15:53 CET
Market cap
135.34 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-122.23 USD m
Free cash flow, TTM
-81.69 USD m
EPS diluted, TTM
-1.25
P/E
-
Compare

Price

ZURA against its 20, 50 and 200-day averages
2050200missearnings
2.004.006.0032.2M64.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ZURAclose 1.4020-day 3.5450-day 4.19200-day 5.121.40

81.2% under 7.44 on 10 Mar 2026. Last 15 sessions, 392.5% high to low

Profile

ZURA
52-week range, 7% of the way up
0.937.44

Zura Bio Ltd. is a clinical-stage, multi-asset immunology company, which engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company was founded by Someit Sidhu on January 18, 2022 and is headquartered in Henderson, NV.

IndexRUT
Employees40
IPOSep 03, 2021
Beta0.12
ATR, 14d0.56
Rel volume1.20
Short float16.74%
Insider own47.45%
Inst own60.09%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap134.85M
Enterprise Value-52.80M
Income-122.23M
Sales0.00M
Book/sh1.84
Cash/sh1.95
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees40
IPOSep 03, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.76
P/C0.72
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio11.29
Current Ratio11.29
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.25
EPS next Y-0.77
EPS next Q-0.20
EPS this Y21.75%
EPS next Y7.18%
EPS next 5Y10.02%
EPS past 3/5Y80.48% -
Sales past 3/5Y- -
EPS Y/Y TTM-76.37%
Sales Y/Y TTM-
EPS Q/Q4.58%
Sales Q/Q-
EarningsOct 27 BMO
EPS/Sales Surpr.1.91% -

Ownership

Insider Own47.45%
Insider Trans0.00%
Inst Own60.09%
Inst Trans8.20%
ROA-72.21%
ROE-85.51%
ROIC-68.80%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-60.49%
SMA50-66.63%
SMA200-72.67%
Trades-

Technical

Shs Outstand96.31M
Shs Float50.62M
Short Float16.74%
Short Ratio2.09
Short Interest8.47M
52W High7.44 -81.18%
52W Low0.93 49.85%
Volatility19.69% 14.85%
ATR (14)0.56
RSI (14)26.86
Beta0.12
Rel Volume1.20
Avg Volume4.04M
Volume516,450

Performance

Perf Week-65.18%
Perf Month-66.91%
Perf Quarter-75.13%
Perf Half Y-70.84%
Perf YTD-73.28%
Perf Year-68.33%
Perf 3Y-67.29%
Perf 5Y-85.82%
Perf 10Y-
Recom1.00
Target Price8.33
Prev Close1.40
Price1.40
Change %-0.36%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Jul 08, 2026InitiatedWWilliam BlairOutperform
Feb 09, 2026InitiatedWWedbushOutperform$15+971.5%
Nov 04, 2024InitiatedLLeerink PartnersOutperform$15+971.5%
Sep 05, 2024InitiatedHH.C. WainwrightNeutral$5+257.2%
May 03, 2024InitiatedPPiper SandlerOverweight$26+1,757.3%
Oct 10, 2023InitiatedLLadenburg ThalmannBuy$10+614.3%
Aug 25, 2023InitiatedOOppenheimerOutperform$17+1,114.4%
Jun 22, 2023InitiatedGGuggenheimBuy$20+1,328.7%
Jun 14, 2023InitiatedCChardan Capital MarketsBuy$14+900.1%
May 24, 2023InitiatedRRaymond JamesStrong Buy$20+1,328.7%

Peers

Mkt cap
TickerCompanyMkt cap
AVTXAvalo Therapeutics Inc448.41M
ATTOAttovia Therapeutics Inc770.09M
TRAXFirst Tracks Biotherapeutics Inc2.21B
EVMNEvommune Inc298.14M
MLTXMoonLake Immunotherapeutics1.09B
ZBIOZenas Biopharma Inc1.95B
ANABAnaptysBio Inc1.45B
CTNMContineum Therapeutics Inc424.27M
IMNMImmunome Inc2.24B
CMMBChemomab Therapeutics Ltd ADR9.42M

Insider trading

5 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
SOMEIT SIDHUDirectorAug 18 '26Proposed Sale5.7550,000287,712Aug 18 05:52 PM
SOMEIT SIDHUDirectorAug 17 '26Proposed Sale5.6127,000151,343Aug 17 05:41 PM
SOMEIT SIDHUDirectorAug 14 '26Proposed Sale5.5140,000220,540Aug 14 04:36 PM
SOMEIT SIDHUDirectorAug 13 '26Proposed Sale5.6351,000287,043Aug 13 05:08 PM
AI Biotechnology LLC10% OwnerFeb 26 '26Buy6.252,000,00012,500,0006,552,725Mar 02 05:55 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
IWCiShares Micro-Cap ETFAUM: 1.22B
SBIOALPS Medical Breakthroughs ETFAUM: 192.65M
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B
GSSCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFAUM: 1.06B

News

latest 14 of 89
  • AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning (BioPharma Dive)
  • Zura Bio discontinues tibulizumab in HS after Phase II trial failure (Clinical Trials Arena) +13.31%
  • Zura Bio Discontinues Hidradenitis Suppurativa Development After Phase 2 Tibulizumab Trial Misses Endpoints (InvestorsHub) -69.68%
  • Zura Bio Provides Clinical Update on Phase 2 TibuSHIELD Study of Tibulizumab (ZB-106) in Hidradenitis Suppurativa (Business Wire)
  • Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +19.94%
  • Loading…
  • Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates (Business Wire)
  • This biotech stock is a top pick at Guggenheim (Investing.com) +5.30%
  • Zura Bio to Participate in the Cantor Global Healthcare Conference (Business Wire)
  • Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.69%
  • Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates (Business Wire)
  • Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program (Business Wire) +5.23%
  • Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
  • Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-27-0.200-0.204-0.2000.000.008
2026Q22026-08-11-0.210-0.191-0.2070.000.008
2026Q12026-05-07-0.220-0.174-0.2160.000.008
2025Q42026-03-19-0.490-0.196-0.6230.000.008
2025Q32025-11-13-0.210-0.191-0.2120.000.008
2025Q22025-08-14-0.170-0.188-0.1700.000.006
2025Q12025-05-08-0.190-0.159-0.1880.000.007
2024Q42025-03-25-0.150-0.160-0.1390.000.007
2024Q32024-11-07-0.260-0.131-0.2630.000.007
2024Q22024-08-13-0.170-0.150-0.1690.000.006
2024Q12024-05-09-0.020-0.233-0.0160.000.004
2023Q42024-03-28-0.135-0.230-0.1440.000.005
2023Q32023-11-13-0.180-0.248-0.1760.000.005
2023Q22023-08-14-1.310-0.247-1.3090.000.003
2023Q12023-06-21-2.760-2.760-2.7580.00-1
2026Q4---0.202--0.008

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-2.090-2.624-2.0940.000.00
2024FY-0.600-0.666-0.6050.000.00
2025FY-1.060-0.795-1.0600.000.00
2026FY--0.829--0.00
2027FY--0.770--0.00
2028FY--0.772--6.25
2029FY--0.862--12.50
2030FY--0.703--133.04

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-277000.000.000.00
2026Q4S2026-08-117000.000.000.00
2026Q4S2026-07-307000.000.000.00
2026Q4S2026-07-068000.000.000.00
2026Q4S2026-05-077000.000.000.00
2026Q4S2026-03-207000.000.000.00
2026Q4S2026-02-066000.000.000.00
2026Q4S2025-11-135000.000.000.00
2026Q4S2025-11-115000.000.000.00
2026Q4S2025-11-104000.000.000.00
2026Q4S2025-11-094000.000.000.00
2026Q4S2025-11-084000.000.000.00
2026Q4S2025-11-074000.000.000.00
2026Q4S2025-11-064000.000.000.00

Estimate history

EPS, annual0.397-141.969-2.094-0.605-1.055-1.2482
Period20212022202320242025TTM
EPS, quarterly-0.263-0.139-0.188-0.17-0.212-0.623-0.216-0.207-0.202
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000000
Period20212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual17.250.2843.59465.29873.68196.306
Period20212022202320242025MRQ
Shares, quarterly65.29465.29868.37562.06465.01873.68194.88195.42296.306
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue0.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.070.050.010.000.000.00
Gross Profit-0.07-0.05-0.010.000.000.00
Selling, General and Administrative Excl. Other101.9475.2055.1862.6428.491.09
Research and Development65.9042.0824.4044.0024.85-
Other Operating Expense0.000.000.000.000.000.00
Operating Income-102.00-75.25-55.19-62.64-28.49-1.09
Interest Expense0.000.000.00---
Unusual Expense0.000.005.241.520.16-9.49
Net Income Before Taxes-94.83-68.65-52.40-60.56-28.678.42
Income Taxes-1.300.000.000.000.000.00
Consolidated Net Income-93.53-68.65-52.40-60.56-28.678.42
Net Income From Continuing Operations-122.23-99.35-45.39-60.36-27.008.42
Net Income-122.23-99.35-45.39-69.24-33.978.42
EPS (Recurring)-0.96-1.06-0.56-2.06-148.400.10
EPS (Basic, Before Extraordinaries)-1.25-1.06-0.60-2.09-141.970.40
EPS (Diluted)-1.25-1.06-0.60-2.09-141.970.40
EBITDA-101.94-75.20-55.18-62.64-28.49-1.09
Non-Operating Income (Expense)7.186.608.033.60-0.020.02
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense16.2412.3316.809.660.35-
Price To Earnings Ratio---21.8047.67-
Shares Outstanding96.3173.6865.3043.590.2817.25
Market Capitalization135.34135.34163.23201.25176.12170.26

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.020.020.020.020.010.010.010.01
Gross Profit-0.02-0.02-0.02-0.01-0.01-0.01-0.01-0.01
Selling, General and Administrative Excl. Other28.7529.3125.4818.4019.5118.0519.2515.73
Research and Development19.4920.7114.7510.9611.958.7010.479.24
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-28.77-29.32-25.50-18.41-19.52-18.06-19.25-15.73
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-27.05-26.39-24.22-17.18-18.04-15.99-17.44-13.63
Income Taxes-1.22-0.080.000.000.000.000.000.00
Consolidated Net Income-25.83-26.30-24.22-17.18-18.04-15.99-17.44-13.63
Net Income From Continuing Operations-25.83-26.30-24.22-45.88-20.04-15.99-17.44-9.05
Net Income-25.83-26.30-24.22-45.88-20.04-15.99-17.44-9.05
EPS (Recurring)-0.20-0.21-0.22-0.62-0.21-0.17-0.19-0.14
EPS (Basic, Before Extraordinaries)-0.20-0.21-0.22-0.62-0.21-0.17-0.19-0.14
EPS (Diluted)-0.20-0.21-0.22-0.62-0.21-0.17-0.19-0.14
EBITDA-28.75-29.30-25.48-18.40-19.50-18.05-19.25-15.73
Non-Operating Income (Expense)1.732.941.281.241.482.071.812.11
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.204.465.012.582.383.733.642.82
Shares Outstanding96.3195.4294.8873.6865.0262.0668.3765.30
Market Capitalization135.34560.49564.54340.72281.5364.9788.20163.23

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments109.41176.5099.811.570.73
Short Term Receivables0.000.000.000.000.00
Inventories0.000.000.000.000.00
Other Current Assets2.902.251.040.210.42
Total Current Assets112.31178.74100.841.781.15
Net Property, Plant & Equipment0.130.090.000.000.00
Total Investments and Advances0.000.000.000.00139.40
Intangible Assets--0.000.000.00
Other Assets1.510.700.003.490.00
Total Assets113.95179.53100.845.26140.55
Short Term Debt Incl. Current Port. of LT Debt0.000.000.007.760.00
Accounts Payable0.000.000.000.000.00
Other Current Liabilities12.4119.5120.307.060.27
Total Current Liabilities12.4119.5120.3014.820.27
Long Term Debt0.000.000.0012.500.00
Provision for Risks Charges0.000.000.000.000.00
Other Liabilities0.000.000.990.0010.08
Total Liabilities12.4119.5121.2927.3210.35
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00
Common Equity101.54146.8159.33-32.06130.20
Total Shareholders Equity101.54146.8159.33-32.06130.20
Accumulated Minority Interest0.0013.2020.2210.000.00
Total Equity101.54160.0279.55-22.06130.20
Total Liabilities & Stockholders Equity113.95179.53100.845.26140.55
Book Value Per Share1.382.251.36-114.607.55
Tangible Book Value Per Share1.382.251.36-114.607.55
Full-Time Employees403015--
Price to Book Ratio0.761.073.181.331.31
Return on Assets-67.71-32.38-49.81-37.03-
Return on Equity-80.01-44.03-62.52-55.01-
Return on Invested Capital-97.85-30.91-101.74-6.46
Quick Ratio9.059.164.970.124.23
Current Ratio9.059.164.970.124.23

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-93.53-68.65-52.40-60.56-27.336.85
Depreciation0.070.050.01---
Other Funds (Non Cash)12.437.4222.0140.3922.59-7.71
Funds from Operations-83.61-61.18-30.38-20.17-4.74-0.86
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital2.01-3.632.315.123.54-0.24
Cash from Operating Activities-81.60-64.82-28.08-15.05-1.20-1.10
Capital Expenditures-0.09-0.11-5.08-8.00-12.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.00-139.38
Purchase of Investments0.000.000.000.000.00-139.38
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.09-0.11-5.08-8.00-12.00-139.38
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock137.795.20110.79132.4810.00140.82
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock137.795.20110.79132.4810.00140.82
Proceedsfrom Stock Options134.575.09110.79132.4810.00140.82
Issuance or Reduction of Debt, Net0.000.000.00-10.007.60-0.12
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-7.46-7.37-0.94-1.18-2.830.51
Other Financing Activities Uses-7.46-7.37-0.94-1.18-2.830.00
Cash from Financing Activities130.33-2.16109.84121.2914.77141.21
Net Change in Cash48.64-67.0976.6998.241.570.73
Free Cash Flow-81.69-64.93-28.15-15.05-1.20-1.10
Preferred Dividends (Cash Flow)-0.000.00-0.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments187.65205.13225.59109.41139.02154.49
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets3.945.371.412.903.272.50
Total Current Assets191.59210.50227.00112.31142.29156.99
Net Property, Plant & Equipment0.150.150.120.130.130.12
Total Investments and Advances0.000.000.000.000.000.00
Other Assets2.882.751.511.511.510.70
Total Assets194.63213.40228.64113.95143.94157.81
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable0.000.000.000.000.000.00
Income Tax Payable1.282.67----
Other Current Liabilities15.6913.6411.7412.4125.4918.70
Total Current Liabilities16.9716.3211.7412.4125.4918.70
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities16.9716.3211.7412.4125.4918.70
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity177.66197.09216.90101.54108.24125.91
Total Shareholders Equity177.66197.09216.90101.54108.24125.91
Accumulated Minority Interest0.000.000.000.0010.2013.20
Total Equity177.66197.09216.90101.54118.44139.11
Total Liabilities & Stockholders Equity194.63213.40228.64113.95143.94157.81
Book Value Per Share1.842.072.291.381.662.03
Tangible Book Value Per Share1.842.072.291.381.662.03
Full-Time Employees---40--
Price to Book Ratio0.762.584.323.152.130.52
Return on Assets-72.21-62.74-52.92-67.71-37.55-37.68
Return on Equity-85.51-72.10-59.78-80.01-47.86-46.33
Return on Invested Capital-14.54-13.35-11.17-45.19-18.51-12.70
Quick Ratio11.2912.9019.339.055.588.40
Current Ratio11.2912.9019.339.055.588.40

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-25.83-26.30-24.22-17.18-18.04-15.99
Depreciation0.020.020.020.020.010.01
Other Funds (Non Cash)5.334.505.01-2.412.393.78
Funds from Operations-20.31-24.54-19.19-19.57-15.64-12.21
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.813.640.27-2.710.20-3.82
Cash from Operating Activities-19.50-20.90-18.92-22.28-15.44-16.03
Capital Expenditures-0.04-0.02-0.01-0.02-0.03-0.02
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.04-0.02-0.01-0.02-0.03-0.02
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock2.180.47135.120.020.090.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.180.47135.120.020.090.00
Proceedsfrom Stock Options0.00-0.55135.120.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.00-0.090.00
Change in Long Term Debt0.000.000.000.00-0.090.00
Issuance of Long Term Debt0.000.000.000.00-0.090.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.130.000.00-7.330.00-0.03
Other Financing Activities Uses-0.130.000.00-7.330.00-0.03
Cash from Financing Activities2.050.47135.12-7.320.00-0.03
Net Change in Cash-17.48-20.46116.19-29.61-15.47-16.08
Free Cash Flow-19.53-20.93-18.94-22.30-15.48-16.05

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3016.74%8.5M50.6M2.67M
2026-10-1513.94%7.0M50.4M1.95M
2026-09-3018.60%9.4M50.4M1.32M
2026-09-1518.55%9.3M50.4M1.36M
2026-08-3122.21%11.1M50.0M1.30M
2026-08-1422.90%11.4M50.0M1.09M
2026-07-3116.61%10.5M63.3M1.06M
2026-07-1516.20%10.3M63.3M1.08M
2026-06-3014.61%9.2M63.3M996.18K
2026-06-159.26%5.9M63.4M731.08K
2026-05-299.82%6.2M63.4M622.04K
2026-05-159.79%6.2M63.8M616.40K
2026-04-3010.32%7.0M67.6M568.50K
2026-04-159.12%6.2M67.5M654.97K
2026-03-319.95%5.8M57.9M671.94K
2026-03-138.82%5.1M57.9M674.51K
2026-02-279.01%4.7M52.6M655.36K
2026-02-1310.28%4.1M39.7M611.51K
2026-01-309.23%3.8M41.7M632.19K
2026-01-157.23%3.0M41.7M539.82K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.004.900.000.0000.000.000.941-0.0080.000
call1.000.350.500.353.5162,1791.000.852-0.0070.001
call1.500.000.800.156.33053.001.000.674-0.0290.001
call2.000.000.100.00-37.000.00---
call2.500.004.900.023.8763990.000.257-0.0150.001
call4.000.000.050.044.3421,6840.000.132-0.0110.000
call5.000.000.050.045.1249,4460.000.121-0.0130.000
call6.000.000.050.055.4002850.000.115-0.0120.000
call7.500.000.050.025.9448,5490.000.108-0.0130.000
call9.000.000.050.016.3721,2120.000.104-0.0130.000
call10.000.000.050.046.6131,0500.000.102-0.0140.000
put0.500.000.050.00-0.000.00---
put1.000.000.050.022.4041,4780.00-0.146-0.0060.001
put1.500.000.800.008.8590.000.00-0.326-0.0290.001
put2.000.004.900.008.2131850.00-0.700-0.0120.001
put2.500.151.151.102.9533,2210.00-0.743-0.0150.001
put4.001.705.002.850.0009170.00-0.868-0.0110.000
put5.001.106.003.900.00054.000.00-0.878-0.0120.000
put6.002.107.002.870.00079.000.00-0.885-0.0130.000
put7.503.608.503.740.0007.000.00-0.891-0.0130.000
put9.005.1010.000.000.0000.000.00-0.896-0.0140.000
put10.006.1011.006.100.0000.000.00-0.898-0.0140.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-098-KCurrent report2026-11-09SEC
2026-11-03EFFECTEffectiveness filing by commission orderSEC
2026-10-278-KCurrent report2026-10-27SEC
2026-10-2710-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-27S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-09-30S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-178-KCurrent report2026-08-17SEC
2026-08-14144Filing for proposed sale of securities under Rule 144.SEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-018-KCurrent report2026-07-01SEC
2026-06-223Initial statement of beneficial ownership of securities2026-04-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-188-KCurrent report2026-06-17SEC
2026-05-22DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-05-228-KCurrent report2026-05-20SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-12SCHEDULE 13G/ASEC
2026-05-078-KCurrent report2026-05-07SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-0212.50M100
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
MONTANOVA CAPITAL, LLC9.94%
Venrock Adviser, LLC6.77%
MPM BioImpact LLC4.71%
JPMORGAN CHASE & CO4.58%
GREAT POINT PARTNERS LLC4.44%
BRAIDWELL LP4.19%
Siren, L.L.C.3.93%
BlackRock, Inc.3.81%
Commodore Capital LP3.42%
ADAGE CAPITAL PARTNERS GP, L.L.C.2.89%

Funds

Fund% owned
iShares Russell 2000 ETF1.54%
VANGUARD EXTENDED MARKET INDEX FUND0.79%
Fidelity Small Cap Index Fund0.68%
iShares Russell 2000 Growth ETF0.58%
Select Biotechnology Portfolio0.53%
VANGUARD RUSSELL 2000 INDEX FUND0.35%
Fidelity Extended Market Index Fund0.33%
iShares Micro-Cap ETF0.21%
Schwab Small-Cap Index Fund0.15%
Fidelity Total Market Index Fund0.14%

OakChart. ZURA. Cached 15 minutes.